



165 34
RECEIVED

JAN 22 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Martin S. Linsell et al.

Title: POLYACID GLYCOPEPTIDE DERIVATIVES

Docket No.: 1343.001US1

Serial No.: 09/847,041

Filed: May 1, 2001

Due Date: N/A

Examiner: Unknown

Group Art Unit: Unknown


Commissioner for Patents
Washington, D.C. 20231

We are transmitting herewith the following attached items (as indicated with an "X"):

- ☒ A return postcard.
- ☒ An Information Disclosure Statement (1 p.), Form 1449 (2 p.), and copies of 23 cited references.


Please consider this a **PETITION FOR EXTENSION OF TIME** for sufficient number of months to enter these papers and please charge any additional required fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)

By: 
Atty: Robert J. Harris, Ph.D.
Reg. No. 37,346

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on this 6th day of November, 2001.

Alisia G. Dunbar
Name


Signature

Customer Number 21186

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
(GENERAL)

P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)

S/N 09/847,041

JAN 15 2002

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Martin S. Linsell et al.

Examiner: Unknown

Serial No.: 09/847,041

Group Art Unit: Unknown

Filed: May 1, 2001

Docket: 1343.001US1

Title: POLYACID GLYCOPEPTIDE DERIVATIVES

TECH CENTER 1600/2900

JAN 22 2002

RECEIVED

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants further request that a copy of the 1449 form, initialled by the Examiner to indicate that all listed citations have been considered, be returned with the next official communication.

Under 37 C.F.R. §1.97(b)(3), it is believed that no fee or certificate is required with this Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge any additional fees or credit any overpayment to Account No. 19-0743.

The Examiner is invited to contact the Applicants' Representatives at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

MARTIN S. LINSELL ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 359-3265

Date

11-8-01

By

Robert J. Harris, Ph.D.
Reg. No. 37,346

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner of Patents, Washington, D.C. 20231, on this 8th day of November, 2001.

Alisia G Dunbar

Name

Signature



Sheet 2

Form 1449*	Atty. Docket No.: 1343.001US1	Serial No. 09/847,041
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Martin S. Linsell et al.	
	Filing Date: May 1, 2001	Group: Unknown

OTHER DOCUMENTS

**Examiner
Initial

(Including Author, Title, Date, Pertinent Pages, Etc.)

	Pavlov, A.Y., et al., "Chemical Modification of Glycopeptide Antibiotics [VC1]", <u>Russian Journal Of Bioorganic Chemistry</u> , 24 (9), pp. 570-587, (1998)
	Pavlov, A.Y., et al., "Mono and Double Modified Teicoplanin Aglycon Derivatives on the Amino Acid No. 7; Structure-activity Relationship", <u>The Journal of Antibiotics</u> , 51 (1), pp. 73-78, (Jan. 1998)
	Zhang, M., et al., "A review of recent applications of cyclodextrins for drug discovery", <u>Expert Opinion on Therapeutic Patents</u> , 9 (12), 21 p., (1999)

Examiner

Date Considered

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

TECH CENTER 1600/2900

JAN 22 2002